plavix has been researched along with enalaprilat anhydrous in 1 studies
Studies (plavix) | Trials (plavix) | Recent Studies (post-2010) (plavix) | Studies (enalaprilat anhydrous) | Trials (enalaprilat anhydrous) | Recent Studies (post-2010) (enalaprilat anhydrous) |
---|---|---|---|---|---|
7 | 0 | 5 | 846 | 109 | 76 |
Protein | Taxonomy | plavix (IC50) | enalaprilat anhydrous (IC50) |
---|---|---|---|
Angiotensin-converting enzyme | Mus musculus (house mouse) | 0.0115 | |
Angiotensin-converting enzyme | Homo sapiens (human) | 0.2405 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.0054 | |
Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0012 | |
Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 0.0036 | |
Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.0024 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 other study(ies) available for plavix and enalaprilat anhydrous
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |